Jay S Desgrosellier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1483771/publications.pdf

Version: 2024-02-01

		1163117	1474206
10	4,412	8	9
papers	citations	h-index	g-index
10	10	10	8643
all docs	docs citations	times ranked	citing authors

#	Article	lF	CITATIONS
1	Integrins in cancer: biological implications and therapeutic opportunities. Nature Reviews Cancer, 2010, 10, 9-22.	28.4	3,045
2	Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends in Cell Biology, 2015, 25, 234-240.	7.9	568
3	An integrinÂβ3–KRAS–RalB complex drives tumour stemness and resistance to EGFR inhibition. Nature Cell Biology, 2014, 16, 457-468.	10.3	325
4	An integrin $\hat{l}\pm v\hat{l}^23\hat{a}$ \(\text{"c-Src}\) oncogenic unit promotes anchorage-independence and tumor progression. Nature Medicine, 2009, 15, 1163-1169.	30.7	250
5	Integrin $\hat{l}\pm\hat{vl^2}$ 3 Drives Slug Activation and Stemness in the Pregnant and Neoplastic Mammary Gland. Developmental Cell, 2014, 30, 295-308.	7.0	80
6	Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers. Cancer Discovery, 2017, 7, 1464-1479.	9.4	78
7	Proapoptotic PUMA targets stem-like breast cancer cells to suppress metastasis. Journal of Clinical Investigation, 2017, 128, 531-544.	8.2	38
8	Combined Bcl-2/Src inhibition synergize to deplete stem-like breast cancer cells. Cancer Letters, 2019, 457, 40-46.	7.2	20
9	Stem-like breast cancer cells in the activated state resist genetic stress via TGFBI-ZEB1. Npj Breast Cancer, 2022, 8, 5.	5.2	8
10	A precision approach to breast cancer treatment based on cell lineage-specific vulnerabilities. Oncoscience, 2021, 8, 76-79.	2.2	0